People: Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

2:29am IST
Change (% chg)

$-0.04 (-0.18%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Krasner, Alan 

Dr. Alan Seth Krasner is Chief Medical Officer of the Company. From December 2015 to June 2018, Dr. Krasner served as Global Clinical Development Lead at Shire plc, a global biotechnology company focused on the treatment of rare diseases. Before joining Shire, Dr. Krasner served from May 2008 to November 2015 as Chief Medical Officer for Biodel Inc., a specialty biopharmaceutical company focused on the treatment of diabetes. Prior to Biodel, from 2002 to 2008, Dr. Krasner served as Director in the Department of Clinical Research Metabolic Diseases at Pfizer Global Research and Development, where he was responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner served as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut until July 2017. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently completed his fellowship at Johns Hopkins Hospital in endocrinology and metabolism.

Basic Compensation

Total Annual Compensation, USD 188,920
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,383,040
Fiscal Year Total, USD 1,571,960

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --